Role of Corticosteroids in Reactive Arthritis
Corticosteroids should be used sparingly in reactive arthritis, reserved primarily for short courses of systemic therapy when NSAIDs are insufficient, or as intra-articular injections for localized joint inflammation—not as first-line treatment.
Treatment Algorithm for Reactive Arthritis
First-Line Therapy
NSAIDs constitute the primary treatment for reactive arthritis 1. These should be:
- Used at the minimum effective dose
- Prescribed for the shortest duration possible
- Selected after evaluating gastrointestinal, renal, and cardiovascular risks 2
- Combined with physiotherapy 1
When to Consider Corticosteroids
Systemic glucocorticoids should only be added when NSAIDs provide inadequate symptom control 1. When used:
- Employ the lowest effective dose
- Limit duration to less than 6 months as temporary adjunctive treatment 2
- Recognize they reduce pain and swelling but carry cumulative side effects 2
- Consider them as "bridging therapy" rather than long-term management
Intra-articular corticosteroid injections are preferred over systemic therapy when:
- Inflammation is localized to specific joints
- Rapid relief of local inflammatory symptoms is needed 2
- Systemic side effects need to be minimized 3
Special Considerations
Chlamydia-Induced Reactive Arthritis
This represents a critical exception: antibiotics are mandatory to treat the underlying infection and prevent relapse 1, 3. The sexual partner must also be treated 3.
Chronic/Persistent Cases
When reactive arthritis becomes chronic despite initial management:
- Consider disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine 1, 3
- TNF inhibitors may be used in refractory cases 1
- Avoid prolonged corticosteroid use due to adverse effects 4
Critical Pitfalls to Avoid
Do not use short-term antibiotics routinely except for documented Chlamydia urethritis 3. The evidence shows no benefit for routine antibiotic treatment in reactive arthritis from other pathogens.
Avoid long-term systemic corticosteroids as they carry significant risks including osteoporosis, metabolic disturbances, gastrointestinal complications, and cardiovascular side effects 4. The EULAR guidelines emphasize that cumulative side effects make prolonged use problematic 2.
Do not use corticosteroids as monotherapy—they are adjunctive agents only, meant to bridge patients while other therapies take effect or to manage acute flares 1.
Evidence Quality Note
The recommendations for corticosteroid use in early arthritis come from high-quality EULAR guidelines 2, though these address early arthritis broadly rather than reactive arthritis specifically. The specific literature on reactive arthritis 1, 3 consistently positions corticosteroids as second-line or adjunctive therapy, with NSAIDs remaining the cornerstone of management.